Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A single-dose intranasal live-attenuated codon deoptimized vaccine provides broad protection against SARS-CoV-2 and its variants.
Liu X, Ng WH, Zusinaite E, Freitas J, Taylor A, Yerragunta V, Aavula SM, Gorriparthi S, Ponsekaran S, Bonda RL, Mani P, Nimmagadda SV, Wang S, Lello LS, Zaid A, Dua U, Taft-Benz SA, Anderson E, Baxter VK, Sarkar S, Ling ZL, Ashhurst TM, Cheng SMS, Pattnaik P, Kanakasapapathy AK, Baric RS, Burt FJ, Peiris M, Heise MT, King NJC, Merits A, Lingala R, Mahalingam S. Liu X, et al. Among authors: kanakasapapathy ak. Nat Commun. 2024 Aug 26;15(1):7225. doi: 10.1038/s41467-024-51535-y. Nat Commun. 2024. PMID: 39187479 Free PMC article.
Immunogenicity and safety of HavisureTM vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study.
Susarla SK, Gupta M, Uttam KG, Palkar S, Dhongade AR, Siva Ram Prasad K, Rajapantula V, Ravi MD, Pradeep N, Satish M, Rajashakar BC, Sandhya G, Rajendra L, Sahoo DP, Kanakasapapathy AK. Susarla SK, et al. Among authors: kanakasapapathy ak. Vaccine. 2023 Oct 6;41(42):6215-6220. doi: 10.1016/j.vaccine.2023.08.084. Epub 2023 Sep 1. Vaccine. 2023. PMID: 37661535 Clinical Trial.
A Phase II/III multicenter randomized single blind non-inferiority immunogenicity and safety study of TeddyVac™ vaccine of Human Biologicals Institute in healthy subjects of 10 years to 60 years of age.
Susarla SK, Narang M, Khandgave PN, Patnaik L, Rajapantula V, M S, Bc R, Sahoo DP, Kanakasapapathy AK. Susarla SK, et al. Among authors: kanakasapapathy ak. Infect Dis (Lond). 2024 Oct 8:1-15. doi: 10.1080/23744235.2024.2410466. Online ahead of print. Infect Dis (Lond). 2024. PMID: 39378070